Improvements in DNA technology allow antenatal diagnosis and counseling for couples at risk as early as 8 to 10 weeks after conception. More neonates with hemoglobin Bart's disease are surviving with the advancement of neonatal care and intrauterine transfusion, but have no curative options. Here, we present a patient with hemoglobin Bart's diagnosed and treated in utero, who underwent successful allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA-matched unrelated donor at 5 months of age.
Our patient was born to parents of south Asian descent. He was the product of his mother's fifth pregnancy. The previous four pregnancies had resulted in normal deliveries of healthy infants at term. Our patient was found to have fetal cardiomegaly and pericardial effusion on prenatal ultrasound done at 27 weeks. Hemoglobin Bart's disease was highly suspected, as the mother is a known alpha thalassemia trait carrier. The patient had percutaneous umbilical vein sampling, which revealed, on hemoglobin electrophoresis, that the majority of hemoglobin was hemoglobin Bart's with a small amount of Portland hemoglobin and no hemoglobin A or hemoglobin F. The diagnosis of hemoglobin Bart's disease was confirmed through molecular testing, which revealed deletion of all four alpha globin genes on chromosome 16. Further, infectious disease work-up was negative for CMV, toxoplasmosis and parvovirus. The patient was then closely followed with weekly amniotic fluid index, hydrops checks and biweekly non-stress tests. Fetal echocardiogram done at 30 weeks gestation re-demonstrated the pericardial effusion and the four dilated heart chambers with good function, suggestive of compensated high cardiac output failure. A single intrauterine transfusion was given at 35 weeks gestation, as the middle cerebral arterial doppler time-averaged mean velocity was 42 s.d. above the mean. The baby was born via a normal vaginal delivery at 38 weeks gestation. APGAR scores at 1 and 5 min were 9 and 9, respectively. Initial cardiac examination was within normal limit. Echocardiogram obtained on day-of-life 1 demonstrated a slightly dilated chamber, large patent ductus arteriosus with bidirectional flow, small patent foramen ovale and a small rim of pericardial effusion. A treatment plan of transfusions and iron monitoring was decided upon, with counseling about HSCT.
At 5 months of age, he was admitted for HSCT from a 10/10 HLA-matched unrelated donor, following conditioning with IV busulfan (targeting a concentration steady state of 750 ng/mL), fludarabine 160 mg/m 2 and rabbit ATG 8 mg/kg. He received a bone marrow graft containing 8.4 ×10 8 /kg nucleated cells. Graft versus host disease prophylaxis consisted of cyclosporine and short-course methotrexate. A cyclosporine taper was initiated 100 days post transplant and the drug discontinued at 6 months post transplant. The early transplant course was complicated by severe sinusoidal obstruction syndrome (SOS) and grade 4 mucositis. On day +11 the patient was transferred to the pediatric intensive care unit for respiratory distress caused by his mucositis. Moderate SOS diagnosed on day +13 based on modified Seattle criteria 4 showed 42% weight gain from baseline, peripheral edema and hepatomegaly. Doppler ultrasound of the liver demonstrated retrograde flow in the hepatic vein. He remained intubated for a total of 18 days. The SOS was treated with antithrombin III for 24 days and completely resolved. Neutrophil and platelet engraftment were achieved on day +25 and +42, respectively. His last packed red blood cell transfusion was administered on day +36, and he was discharged home on day +55. Chimerism studies on peripheral blood performed by satellite tandem repeat analysis on day +30 showed 495% CD33+ donor cells. Interestingly, the percent donor CD33+ cells started to decline at 6 months post-transplant but stabilized 12-20 months post transplant between 15 and 20%. The percent CD3+ donor cells have remained between 78 and 95%. Hemoglobin electrophoresis done at 1 year post transplant showed 97% hemoglobin A1, 2.8% HBG A2 and 0.2% HBG F. Hemoglobin Bart's was detected at a very low level, which could not be quantified.
While hemoglobin Bart's hydrops commonly occurs in southeast Asia and the Mediterranean area, global migration has led to an increased incidence in Europe and North America. Until the wide availability of premarital screening and antenatal diagnosis, many cases resulted in stillbirth or other maternal obstetric complications. Intravascular intrauterine exchange transfusions can result in survival of the affected fetuses, which makes early diagnosis important to ensure better outcomes. 3 HSCT for children with homozygous beta thalassemia is offered by many centers around the world. However, there are only three case reports of successful HSCT in children with hemoglobin Bart's disease. The first two cases were diagnosed postnatally and both neonates required cardiopulmonary resuscitation at birth. Chik et al. 5 reported on a successful matched sibling bone marrow transplant in a 21-month-old girl with hemoglobin Bart's disease. There were no serious complications reported in the peri-transplant period. Chimerism studies done on whole blood using fluorescent in situ hybridization analysis of sex chromosomes showed mixed chimerism from 2 months post-transplant onward. Donor cells ranged from 99.0 to 79.0%. Despite mixed chimerism noticed, the patient hemoglobin remained stable without significant fluctuation up to the time of the report 20 months post-transplant. Zhou et al. 6 reported on an umbilical cord blood transplant in a 20-month-old girl with hemoglobin Bart's disease utilizing a sibling, mismatched at one MHC locus. Busulfan, cyclophosphamide and ATG were used for conditioning in both cases and sustained engraftment was achieved. Thornley et al. 7 reported a patient with hemoglobin Bart's disease diagnosed and treated in utero, who underwent successful HSCT from his HLA-matched sister at 23 months of age after conditioning with cyclophosphamide and TBI. The early transplant course was complicated by mild SOS. The patient was 3 years post transplant at the time of their report without further complications.
Our patient is the youngest child reported to have received a bone marrow transplant, and the first case to utilize an unrelated bone marrow donor. He experienced a difficult post-transplant course with development of moderate SOS and severe mucositis, which might have contributed to delayed neutrophil and platelet engraftment, though both conditions resolved with appropriate therapy. The observation that red blood cell transfusion independence has been maintained, despite stable but low level CD33+ donor chimerism, suggests that a reduced-intensity conditioning regimen could be considered in this clinical setting.
In conclusion, neonates with hemoglobin Bart's disease are now surviving with the advancement of neonatal care and intrauterine transfusion; however, there are significant morbidities associated with lifelong transfusion dependence. Allogeneic HSCT offers a chance of cure for hemoglobin Bart's disease, similar to patients with beta thalassemia major, and should be considered utilizing the best available donor.
